These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9725544)

  • 1. Effect of hepatic impairment on the pharmacokinetics of zolmitriptan.
    Dixon R; French S; Kemp J; Sellers M; Leclerc V; Delvaux M; Rautureau J
    J Clin Pharmacol; 1998 Aug; 38(8):694-701. PubMed ID: 9725544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults.
    Dixon R; Engleman K; Kemp J; Ruckle JL
    J Child Adolesc Psychopharmacol; 1999; 9(1):35-42. PubMed ID: 10357516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical pharmacokinetics of zolmitriptan.
    Dixon R; Warrander A
    Cephalalgia; 1997 Oct; 17 Suppl 18():15-20. PubMed ID: 9399013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90).
    Peck RW; Seaber EJ; Dixon R; Gillotin CG; Weatherley BC; Layton G; Posner J
    Br J Clin Pharmacol; 1997 Dec; 44(6):595-9. PubMed ID: 9431839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study.
    Smith DA; Cleary EW; Watkins S; Huffman CS; Dilzer SC; Lasseter KC
    J Clin Pharmacol; 1998 Aug; 38(8):685-93. PubMed ID: 9725543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers.
    Dixon R; Gillotin C; Gibbens M; Posner J; Peck RW
    Br J Clin Pharmacol; 1997 Mar; 43(3):273-81. PubMed ID: 9088582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).
    Seaber E; On N; Dixon RM; Gibbens M; Leavens WJ; Liptrot J; Chittick G; Posner J; Rolan PE; Pack RW
    Br J Clin Pharmacol; 1997 Jun; 43(6):579-87. PubMed ID: 9205817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers.
    Seaber EJ; Peck RW; Smith DA; Allanson J; Hefting NR; van Lier JJ; Sollie FA; Wemer J; Jonkman JH
    Br J Clin Pharmacol; 1998 Nov; 46(5):433-9. PubMed ID: 9833595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women.
    Peck RW; Seaber EJ; Dixon RM; Layton GR; Weatherley BC; Jackson SH; Rolan PE; Posner J
    Clin Pharmacol Ther; 1998 Mar; 63(3):342-53. PubMed ID: 9542478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90).
    Rolan P
    Cephalalgia; 1997 Oct; 17 Suppl 18():21-7. PubMed ID: 9399014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide.
    Seaber EJ; Ridout G; Layton G; Posner J; Peck RW
    Eur J Clin Pharmacol; 1997; 53(3-4):229-34. PubMed ID: 9476036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis.
    Gillotin C; Bagnis C; Mamet JP; Peck RW; Deray G
    Int J Clin Pharmacol Ther; 1997 Nov; 35(11):522-6. PubMed ID: 9401835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers.
    Yates R; Nairn K; Dixon R; Seaber E
    J Clin Pharmacol; 2002 Nov; 42(11):1237-43. PubMed ID: 12412822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zolmitriptan (311C90) does not interact with fluoxetine in healthy volunteers.
    Smith DA; Cleary EW; Watkins S; Huffman CS; Polvino WJ
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):301-5. PubMed ID: 9660035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan.
    Edmeads JG; Millson DS
    Cephalalgia; 1997 Oct; 17 Suppl 18():41-52. PubMed ID: 9399016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, dose proportionality, and tolerability of single and repeat doses of a nasal spray formulation of zolmitriptan in healthy volunteers.
    Yates R; Nairn K; Dixon R; Kemp JV; Dane AL
    J Clin Pharmacol; 2002 Nov; 42(11):1244-50. PubMed ID: 12412823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group.
    Rapoport AM; Ramadan NM; Adelman JU; Mathew NT; Elkind AH; Kudrow DB; Earl NL
    Neurology; 1997 Nov; 49(5):1210-8. PubMed ID: 9371896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zolmitriptan. Introduction.
    Mathew N
    Cephalalgia; 1997 Oct; 17 Suppl 18():1-3. PubMed ID: 9399011
    [No Abstract]   [Full Text] [Related]  

  • 19. The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects.
    Yates RA; Tateno M; Nairn K; Ikegami A; Dane A; Kemp J
    Eur J Clin Pharmacol; 2002 Jul; 58(4):247-52. PubMed ID: 12136370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.
    Van Haarst AD; Van Gerven JM; Cohen AF; De Smet M; Sterrett A; Birk KL; Fisher AL; De Puy ME; Goldberg MR; Musson DG
    Br J Clin Pharmacol; 1999 Aug; 48(2):190-6. PubMed ID: 10417495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.